These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30108938)

  • 1. Design, synthesis and evaluation of (
    Chough C; Lee S; Joung M; Lee J; Kim JH; Kim BM
    Medchemcomm; 2018 Mar; 9(3):477-489. PubMed ID: 30108938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.
    Chough C; Joung M; Lee S; Lee J; Kim JH; Kim BM
    Bioorg Med Chem; 2018 May; 26(8):1495-1510. PubMed ID: 29452839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-guided design of potent JAK1-selective inhibitors based on 4-amino-7H-pyrrolo[2,3-d]pyrimidine with anti-inflammatory efficacy.
    Zhang J; Xing S; Cui J; Wei X; Cao Z; Shao B; Jiang N; Zhai X
    Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300591. PubMed ID: 38185750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and anti-inflammatory evaluation of novel pyrrolo[2,3-d]pyrimidin derivatives as potent JAK inhibitors.
    Jiang F; Zang L; Miao X; Jia F; Wang J; Zhu M; Gong P; Jiang N; Zhai X
    Bioorg Med Chem; 2019 Sep; 27(18):4089-4100. PubMed ID: 31378597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).
    Jiang JK; Ghoreschi K; Deflorian F; Chen Z; Perreira M; Pesu M; Smith J; Nguyen DT; Liu EH; Leister W; Costanzi S; O'Shea JJ; Thomas CJ
    J Med Chem; 2008 Dec; 51(24):8012-8. PubMed ID: 19053756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
    Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
    J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Chloro-N-[2-(1H-imidazol-4-yl)eth-yl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine.
    Richter D; Kath JC; Rheingold AL; Dipasquale A; Yanovsky A
    Acta Crystallogr Sect E Struct Rep Online; 2009 Dec; 66(Pt 1):o242. PubMed ID: 21580123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents.
    Kimura Y; Atarashi S; Kawakami K; Sato K; Hayakawa I
    J Med Chem; 1994 Sep; 37(20):3344-52. PubMed ID: 7932562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
    J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of
    Zhu Y; Ma Y; Zu W; Song J; Wang H; Zhong Y; Li H; Zhang Y; Gao Q; Kong B; Xu J; Jiang F; Wang X; Li S; Liu C; Liu H; Lu T; Chen Y
    J Med Chem; 2020 Jul; 63(13):6748-6773. PubMed ID: 32479083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.
    Vidadala RSR; Golkowski M; Hulverson MA; Choi R; McCloskey MC; Whitman GR; Huang W; Arnold SLM; Barrett LK; Fan E; Merritt EA; Van Voorhis WC; Ojo KK; Maly DJ
    ACS Infect Dis; 2018 Apr; 4(4):516-522. PubMed ID: 29522315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.
    Park E; Park S; Lee SJ; Jeong D; Jin H; Moon H; Cha B; Kim D; Ma S; Seo W; Han SH; Lee YS; Kang S
    J Med Chem; 2023 Dec; 66(23):16342-16363. PubMed ID: 38031930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine inhibits the proliferation and migration of vascular smooth muscle cells by suppressing ERK and Akt pathways.
    Seo HH; Kim SW; Lee CY; Lim KH; Lee J; Lim S; Lee S; Hwang KC
    Eur J Pharmacol; 2017 Mar; 798():35-42. PubMed ID: 28185804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, Synthesis, and Characterization of Novel Baricitinib Impurities.
    Vaddamanu G; Goswami A; Reddy NRS; Kumar Reddy KRV; Mulakayala N
    ACS Omega; 2023 Mar; 8(10):9583-9591. PubMed ID: 36936292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
    Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
    Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of hydrazinyl-containing pyrrolo[2,3-d]pyrimidine series as potent, selective and oral JAK1 inhibitors for the treatment of rheumatoid arthritis.
    Mao W; Wu H; Guo Q; Zheng X; Wei C; Liao Y; Shen L; Mi J; Li J; Chen S; Qian W
    Bioorg Med Chem Lett; 2022 Oct; 74():128905. PubMed ID: 35870730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
    Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
    J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.